Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
1don MSN
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...
1d
LGBTQ Nation on MSNOnce-a-year shot for HIV protection passes early safety trialAn annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
19h
The Montgomery Advertiser on MSNAlabama still fighting HIV: 'In the South is where we have the majority of the problems':Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...
Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results